首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3652篇
  免费   295篇
  国内免费   24篇
耳鼻咽喉   22篇
儿科学   445篇
妇产科学   14篇
基础医学   472篇
口腔科学   27篇
临床医学   128篇
内科学   72篇
皮肤病学   959篇
神经病学   361篇
特种医学   41篇
外科学   160篇
综合类   375篇
预防医学   154篇
眼科学   37篇
药学   307篇
  2篇
中国医学   381篇
肿瘤学   14篇
  2023年   57篇
  2022年   71篇
  2021年   100篇
  2020年   146篇
  2019年   109篇
  2018年   114篇
  2017年   122篇
  2016年   130篇
  2015年   123篇
  2014年   304篇
  2013年   243篇
  2012年   253篇
  2011年   263篇
  2010年   192篇
  2009年   179篇
  2008年   138篇
  2007年   163篇
  2006年   136篇
  2005年   107篇
  2004年   102篇
  2003年   83篇
  2002年   83篇
  2001年   72篇
  2000年   60篇
  1999年   55篇
  1998年   46篇
  1997年   34篇
  1996年   38篇
  1995年   27篇
  1994年   25篇
  1993年   50篇
  1992年   25篇
  1991年   19篇
  1990年   32篇
  1989年   28篇
  1988年   25篇
  1987年   23篇
  1986年   16篇
  1985年   24篇
  1984年   19篇
  1983年   11篇
  1982年   14篇
  1981年   12篇
  1980年   9篇
  1979年   13篇
  1978年   16篇
  1977年   13篇
  1976年   9篇
  1975年   14篇
  1972年   7篇
排序方式: 共有3971条查询结果,搜索用时 15 毫秒
1.
慢性湿疹是皮肤科常见疾病,其病因复杂,单一通过西医治疗手段效果欠佳。医者临床中总结出"木火刑金"是慢性湿疹的病机之一,以疏肝解郁、补益肺气之法治疗慢性湿疹效果良好。  相似文献   
2.
[目的] 介绍重用黄芪之经方联用治疗四则疑难重症的体会。[方法] 通过整理、分析临床治疗心包积液、不明原因单侧上肢肿胀疼痛、湿疹重症、黄汗重症四则验案,总结联合运用经方且重用黄芪,发挥其利水之功效治疗疑难重症的经验。[结果] 黄芪具有益气固表、利水消肿的功效,临床上黄芪用量达80~100 g可发挥其利水之功。结合患者整体临床表现,验案一选用防己黄芪汤、枳实薤白桂枝汤等以温振心阳、化气利水;验案二选用黄芪桂枝五物汤、防己地黄汤等以活血通阳、利水燥湿;验案三选用桂枝加黄芪汤、麻黄连轺赤小豆汤等以祛风散邪、清利湿热;验案四选用芪芍桂酒汤、防己茯苓汤等以通调气血、行水利湿,治疗后临床效果显著。[结论] 临床上遵循“观其脉证,知犯何逆,随证治之”的原则联合应用经方,以疾病症状体征为导向,谨守病因病机遣方用药,能治疗多种疑难重症。  相似文献   
3.
Network meta-analyses (NMAs) simultaneously estimate the effects of multiple possible treatment options for a given clinical presentation. For allergists to benefit optimally from NMAs, they must understand the process and be able to interpret the results. Through a worked example published in Pediatric Allergy and Immunology, we summarize how to identify credible NMAs and interpret them with a focus on recent innovations in the GRADE approach (Grading of Recommendations Assessment, Development, and Evaluation). NMAs build on traditional systematic reviews and meta-analyses that consider only direct paired comparisons by including indirect evidence, thus allowing the simultaneous assessment of the relative effect of all pairs of competing alternatives. Our framework informs clinicians of how to identify credible NMAs and address the certainty of the evidence. Trustworthy NMAs fill a critical gap in providing key inferences using direct and indirect evidence to inform clinical decision making when faced with more than two competing courses of treatment options. This document will help allergists to identify trustworthy NMAs to enhance patient care.  相似文献   
4.
目的:探讨卿氏湿疹泡洗方2号对血虚风燥型手足慢性湿疹的效果。方法:选取我院2018年1月-2018年9月血虚风燥型手足慢性湿疹患者116例,根据治疗方案不同分为研究组(58例)和参照组(58例),参照组给予卤米松乳膏联合尿素乳膏,研究组给予卿氏湿疹疱洗方2号联合尿素乳膏,比较两组治疗效果、治疗前后湿疹面积及严重度指数(Eczema Area and Severity Index,EASI)、皮肤病生活质量指数(Dermatology life uality Index,DLQI)及不良反应。结果:研究组治疗总有效率为94.83%(55/58),高于参照组82.76%(48/58)(P<0.05);两组治疗后EASI、DLQI评分均低于治疗前,且研究组低于参照组(P<0.05);两组均未见严重不良反应。结论:卿氏湿疹泡洗方2号治疗血虚风燥型手足慢性湿疹患者疗效确切,可明显改善临床症状,缩小湿疹面积,提高患者生活质量,且不增加不良反应,安全性高,值得临床推广应用。  相似文献   
5.
目的观察蒲地蓝消炎口服液联合应用氢定乳膏治疗PICC局部湿疹的疗效。方法采用病例对照研究的方法,选择PICC门诊2014年1月-2018年12月PICC局部湿疹患者80例,随机分为实验组39例和对照组41例,观察组用蒲地蓝消炎口服液联合氢定乳膏加局部敷料开窗法进行护理。对照组用氢定乳膏加局部敷料开窗法,比较2组的临床疗效。结果观察组39例,总有效34例(87.18%);对照组41例,总有效23例(56.10%)。2组比较差异具有统计学意义(P<0.01)。结论蒲地蓝消炎口服液联合氢定乳膏治疗PICC局部湿疹的效果优于对照组。  相似文献   
6.
ABSTRACT

Introduction: Skin conditions are common and highly varied in their etiology; therefore, a diverse array of therapeutics are utilized. Drug safety studies in dermatology can be challenging as there are over 3000 diagnoses to consider. As a result, dermatologists rely on data from multiple sources including clinical trials and real-world evidence.

Areas covered: In this review, we cover the main sources of safety data available, their strengths and weaknesses and how dermatologists should utilize such data. We use real-world examples of the different types of adverse events reported and how they are best captured by either randomized controlled trials or post-marketing pharmacovigilance methods. With multiple new therapies in dermatology, such as dupilumab for atopic dermatitis and janus-kinase inhibitors for alopecia areata the specialty is awash with evolving high-level evidence for their use. It is important to understand the optimal way to assess safety from trials but also appreciate the need for ongoing capture of safety data in clinical practice.

Expert opinion: In dermatology, there is a plethora of conditions to treat and clinical trials, post-marketing surveillance, such as drug registries and spontaneous reporting, all enable dermatologists to gain a more comprehensive understanding of the safety profiles of drugs being used.  相似文献   
7.
《中国现代医生》2020,58(32):11-14
目的 分析复方甘草酸苷联合盐酸左西替利嗪治疗皮炎湿疹的效果及对Th1/Th2 型细胞因子的影响。方法 选取2018 年10 月~2019 年10 月于我院接受治疗的皮炎湿疹患者80 例,分为对照组(40 例)和观察组(40 例)。两组采取不同的方法进行治疗,其中对照组采取盐酸左西替利嗪治疗,观察组采取复方甘草酸苷联合盐酸左西替利嗪治疗。治疗后比较两组患者的Th1/Th2 型细胞因子水平指标及临床疗效。结果 治疗后,观察组的Th1 型细胞因子中的IFN-γ 及IL-2 明显高于对照组,差异有统计学意义(P<0.05)。观察组的Th2 型细胞因子中的IL-4、IgE 与对照组比较,差异有统计学意义(P<0.05)。治疗后,观察组的瘙痒症状分数及糜烂症状分数与对照组比较,差异有统计学意义(P<0.05)。观察组的总有效率明显高于对照组(P<0.05)。结论 对皮炎湿疹患者进行治疗的过程中,使用复方甘草酸苷联合盐酸左西替利嗪进行治疗能够有效改善患者Th1、Th2 型细胞炎症因子,疗效确切,值得推广和应用。  相似文献   
8.
Atopic eczema (AE) is a chronic, itchy, inflammatory skin condition that affects 10–20% of children in developed countries. It is a relapsing and remitting condition, with episodes of disease exacerbation as frequently as two or three times per month. In severe cases it may become continuous. Some children with AE develop lifelong disease whilst others go on to develop asthma and allergic rhinitis, in a sequence referred to as the ‘atopic march’. This article details the current therapies available for treating children with AE, with practical advice on management and reference to the most recent guidelines.  相似文献   
9.
Multiple acyl-CoA dehydrogenase deficiency (MADD), also known as glutaric acidemia type II, is classically caused by a congenital defect in electron transfer flavoprotein (ETF) or ETF dehydrogenase (ETFDH). Flavin adenine dinucleotide synthase (FADS) deficiency caused by mutations in FLAD1 was recently reported as a novel riboflavin metabolism disorder resembling MADD. Here, we describe a Japanese boy with FADS deficiency due to a novel mutation (p.R249*) in FLAD1. In the asymptomatic male infant born at full term, newborn screening showed positive results with elevated C5 and C14:1 acylcarnitine levels and an increased C14:1/C2 ratio. Biochemical studies were unremarkable except for lactic acidosis (pH 7.197, lactate 61 mg/dL). A diagnosis of MADD was suspected because of mild abnormalities of the acylcarnitine profile and apparent abnormalities of urinary organic acids, although mutations in the ETFA, ETFB, ETFDH, and riboflavin transporter genes (SLC52A1, SLC52A2, and SLC52A3) were not detected. Administration of riboflavin and L-carnitine was initiated at one month of age based on the diagnosis of “biochemical MADD” despite a lack of symptoms. Nevertheless, the acylcarnitine profile was not normalized. Symptoms resembling bulbar palsy, such as vocal cord paralysis and dyspnea with stridor, were present from 3 months of age. At 4 months of age, he became bedridden because of hypoxic-ischemic encephalopathy due to fulminant respiratory failure with aspiration pneumonia. At 2 years and 5 months of age, a homozygous c.745C > T (p.R249*) mutation in the FLAD1 gene was identified, confirming the diagnosis of FADS deficiency. His severe clinical course may be caused by this nonsense mutation associated with poor responsiveness to riboflavin. Persistent lactic acidosis and neuropathy, such as bulbar palsy, may be important for diagnosing FADS deficiency. Although the biochemical findings in FADS deficiency are similar to those in MADD, their clinical symptoms and severity may not be identical.  相似文献   
10.
The field of pediatric dermatology treatment has been rich in new developments. Several recent therapeutic advances in pediatric dermatology have been made. This review will focus on critical approach to the new treatments for several entities encountered in pediatric dermatology. The use of biologics and small molecules in children with atopic dermatitis and psoriasis, exciting advances in the use of propranolol and other beta‐blockers for the treatment of infantile hemangiomas, the use of sirolimus for vascular anomalies will be discussed.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号